SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation

University of Cologne

Status and phase: Terminated; Phase 2; Phase 1

Conditions: SARS-CoV-2 Infection

Treatments: Biological: DZIF-10c; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04631705

Uni-Koeln-4370

Details and patient eligibility

About

This is the first-in-human phase 1/2a trial of the inhaled administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals. It will evaluate the safety, pharmacokinetic profile, immunogenicity, and antiviral activity of DZIF-10c.

Full description

The phase 1 component of this trial consists of a single-inhalation open-label dose-escalation phase (Groups 1A-1C and Groups 2A-2C). Subsequently, the highest tolerated dose tested will be administered to an expansion cohort of SARS-CoV-2-infected individuals (Group 2D). In this randomized and blinded group, participants will receive DZIF-10c or placebo both by inhalation and intravenous infusion.

Enrollment: 45 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Groups 1A-1C

• Age 18-65.
• SARS-CoV-2-RNA negative naso- or oropharyngeal swab obtained within 3 calendar days before study drug administration by NAAT (e.g., qRT-PCR).
• Non-reactivity of serum antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological assay at screening.

Groups 2A-2D

• Age 18-70.
• SARS-CoV-2-RNA positive naso- or oropharyngeal swab obtained within 3 calendar days before study drug administration by NAAT (e.g., qRT-PCR).
• Onset of COVID-19 symptoms (e.g., sore throat, cough, fever, chills, fatigue, dys- or anosmia, dys- or ageusia, headache, muscle pain, gastrointestinal symptoms) within 7 days prior to study drug administration or Non-reactivity of serum or plasma antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological assay at screening.
• Disease severity score 1-4 as defined by the WHO Clinical Progression Scale (WHO, Lancet Inf Dis 2020)

Exclusion Criteria (all groups):

• Known hypersensitivity to any constituent of the investigational medicinal product.
• Hepatitis B infection indicated by detectable HBsAg (Hepatitis B surface antigen) in blood.
• Detectable antibodies against hepatitis C virus in blood unless active hepatitis C is ruled out by negative HCV-RNA.
• HIV infection indicated by detectable HIV antigen and/or HIV antibodies in blood.
• Neutrophil count ≤1,000 cells/µl
• Hemoglobin ≤10 g/dl
• Platelet count ≤100,000 cells/µl
• ALT ≥2.0 x ULN
• AST ≥2.0 x ULN
• Total bilirubin ≥1.5 ULN
• eGFR <60 ml/min/1.73m2
• Pregnancy or lactation.
• Any vaccination within 14 days prior to DZIF-10c administration.
• Receipt of any SARS-CoV-2 vaccine or SARS-CoV-2 monoclonal antibody in the past.
• Diagnosis of bronchial asthma or history of bronchial hyperresponsiveness, COPD, pulmonary fibrosis, or other chronic lung diseases.
• Any chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer.
• History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months (a single administration of systemic corticosteroids within ≤6 months and ≥4 weeks of enrollment is acceptable).
• Participation in another clinical trial of an investigational medicinal product within the past 12 weeks or expected participation during this study.
• Dependency on the principal investigator or study staff; or site personnel directly affiliated with this trial.
• Legally incapacitated individuals
• Individuals held in an institution by legal or official order
• If engaging in sexual activity that could result in pregnancy, inability or unwillingness to comply with the requirements for highly effective contraception

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

45 participants in 7 patient groups

Group 1A (uninfected) - low dose

Experimental group

Description:

SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation

Treatment:

Biological: DZIF-10c

Biological: DZIF-10c

Group 1B (uninfected) - mid dose

Experimental group

Description:

SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation

Treatment:

Biological: DZIF-10c

Biological: DZIF-10c

Group 1C (uninfected) - high dose

Experimental group

Description:

SARS-CoV-2-uninfected volunteers will receive a single dose of DZIF-10c by inhalation

Treatment:

Biological: DZIF-10c

Biological: DZIF-10c

Group 2A (infected) - low dose

Experimental group

Description:

SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation

Treatment:

Biological: DZIF-10c

Biological: DZIF-10c

Group 2B (infected) - mid dose

Experimental group

Description:

SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation

Treatment:

Biological: DZIF-10c

Biological: DZIF-10c

Group 2C (infected) - high dose

Experimental group

Description:

SARS-CoV-2-infected volunteers will receive a single dose of DZIF-10c by inhalation

Treatment:

Biological: DZIF-10c

Biological: DZIF-10c

Group 2D (infected)

Experimental group

Description:

SARS-CoV-2-infected volunteers will be randomized 1:1:1 to receive DZIF-10c by inhalation and infusion, DZIF-10c by inhalation and placebo by infusion, or placebo by inhalation and infusion

Treatment:

Drug: Placebo

Biological: DZIF-10c

Drug: Placebo

Biological: DZIF-10c